Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of BridgeBio Pharma's Encaleret?
Encaleret is a small molecule commercialized by BridgeBio Pharma, with a leading Phase III program in Autosomal Dominant Hypocalcemia. According...
Data Insights
Encaleret by BridgeBio Pharma for Autosomal Dominant Hypocalcemia: Likelihood of Approval
Encaleret is under clinical development by BridgeBio Pharma and currently in Phase III for Autosomal Dominant Hypocalcemia. According to GlobalData,...